Clinical Trial Update: TRC105 for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of TRC105 for recurrent glioblastoma was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• TRC105 (carotuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma Multiforme | Phase 2 | Status: TERMINATED | Results posted: 2014-05-12